Hibiscus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.21 Cr
as on 24-10-2024
- Company Age 17 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.85 Cr
as on 24-10-2024
- Revenue 3.97%
(FY 2023)
- Profit 4.59%
(FY 2023)
- Ebitda -1.07%
(FY 2023)
- Net Worth 9.34%
(FY 2023)
- Total Assets 12.16%
(FY 2023)
About Hibiscus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.21 Cr.
The company currently has active open charges totaling ₹1.85 Cr.
Srinivasan Ashalatha, Balabanumathi Venkatesh, Sathiyamurthi Vanisaraswathi, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24230TN2007PTC064251
- Company No.
064251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2007
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Hibiscus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sivasundaran Venkatesh  | Managing Director | 05-Oct-2015 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivasan Ashalatha | Director | 01-Jun-2012 | Current |
| Balabanumathi Venkatesh | Director | 17-Jul-2007 | Current |
| Sathiyamurthi Vanisaraswathi | Director | 20-Feb-2008 | Current |
| Alamelu Priya | Director | 20-Feb-2008 | Current |
| Raju Ranganathan | Director | 25-Aug-2022 | Current |
Financial Performance of Hibiscus Pharmaceuticals.
Hibiscus Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.97% increase. The company also saw a slight improvement in profitability, with a 4.59% increase in profit. The company's net worth moved up by a moderate rise of 9.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hibiscus Pharmaceuticals?
In 2023, Hibiscus Pharmaceuticals had a promoter holding of 93.17% and a public holding of 6.83%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Maruth Medical Centre Salem Private LimitedActive 12 years 2 months
Srinivasan Ashalatha is a mutual person
Charges (Loans)
₹1.85 Cr
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 1.55 Cr
- Others : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Aug 2024 | City Union Bank Limited | ₹2.30 M | Open |
| 22 Nov 2023 | City Union Bank Limited | ₹1.20 Cr | Open |
| 14 Jul 2023 | Others | ₹3.00 M | Open |
| 19 Aug 2011 | City Union Bank Limited | ₹1.23 M | Open |
How Many Employees Work at Hibiscus Pharmaceuticals?
Hibiscus Pharmaceuticals has a workforce of 18 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hibiscus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hibiscus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
